Nebenwirkungen · Fuzeon
Fuzeon 90 mg/ml powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 5
HOS-112403 · Präparat HOS-093667
Table 2 presents events seen at a higher rate among patients receiving Fuzeon + OB regimen than among patients on the OB alone regimen with an exposure adjusted increase of at least 2 patients with event per 100 patient-years. A statistically significant increase was seen for pneumonia and lymphadenopathy. Most adverse reactions were of mild or moderate intensity. Adverse reactions are listed according to MedDRA system organ class and frequency category. Frequency categories are defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-23T14:24:00Z · SHA-256 e89d317a43084b88c577a5e2fa9e8f995c2b6672ed7d5ae08eb316c0043e17cf · Passage 84a5cfe912d09c0276abe3a49e451cb2805d08e3ee7e0ad74d6ef3db2807ccc0 · Zeichen 558–1269 im Abschnitt